Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density

Oncology Letters

Volumn 7, Issue 1, 2014, Pages 95-100

  Zhang, Jing ^a   Yang, Wei ^b   Zhao, Duanyun ^c   Han, Yun ^c   Liu, Bo ^a   Zhao, Hua ^a   Wang, Hongbo ^c   Zhang, Quanzhong ^c   Xu, Guangming ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c HEZE MUNICIPAL HOSPITAL   (China)

Author keywords

Glioma; Microvessel density; Peroxisome proliferator activated receptor ; Thrombospondin 1; Transforming growth factor

Indexed keywords

CD34 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CAPILLARY DENSITY; CHILD; CONTROLLED STUDY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SCORING SYSTEM;

EID: 84888421742     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1650     Document Type: Article

References (26)

1. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al: Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93: 1159-1170, 1998.
2. Presser LD, Haskett A and Waris G: Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-β1: role of TGF-β1 in HCV replication. Virology 412: 284-296, 2011.
3. Recouvreux MV, Camilletti MA, Rifkin DB, Becu-Villalobos D and Diaz-Torga G: Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1). Endocrinology 153: 3861-3871, 2012.
4. Hayashi H, Sakai K, Baba H and Sakai T: Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice. Hepatology 55: 1562-1573, 2012.
5. Nakao T, Kurita N, Komatsu M, et al: Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol 16: 145-152, 2011.
6. Punekar S, Zak S, Kalter VG, et al: Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 75: 9-21, 2008.
7. Reka AK, Kurapati H, Narala VR, et al: Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 9: 3221-3232, 2010.
8. Dong YW, Wang XP and Wu K: Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol 15: 441-448, 2009.
9. Shigeto T, Yokoyama Y, Xin B and Mizunuma H: Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. Oncol Rep 18: 833-840, 2007.
10. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
11. Wang-Rodriguez J, Urquidi V, Rivard A and Goodison S: Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res 5: R136-R143, 2003.
12. Aspiotis M, Tsanou E, Gorezis S, et al: Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye (Lond) 21: 1095-1101, 2007.
13. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E and Pavlidis N: Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer 16 (Suppl 1): 241-246, 2006.
14. Baltaci S, Orhan D, Göǧüs C, Filiz E, Tulunay O and Göǧüs O: Thrombospondin-1, vascular endothelial growth factor expression and microvessel density in renal cell carcinoma and their relationship with multifocality. Eur Urol 44: 76-81, 2003.
15. Hyder SM, Liang Y and Wu J: Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int J Cancer 125: 1045-1053, 2009.
16. Fitchev PP, Wcislak SM, Lee C, et al: Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. Lab Invest 90: 1078-1090, 2010.
17. Byrne GJ, Hayden KE, McDowell G, et al: Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol 31: 1127-1132, 2007.
18. Elpek GO, Gokhan GA and Bozova S: Thrombospondin-1 expression correlates with angiogenesis in experimental cirrhosis. World J Gastroenterol 14: 2213-2217, 2008.
19. Jiang M, Mou CZ, Han T, Wang M and Yang W: Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance. J Int Med Res 40: 1284-1294, 2012.
20. Fontana A, Filleur S, Guglielmi J, et al: Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer 116: 686-691, 2005.
21. Kaygusuz G, Tulunay O, Baltaci S and Gogus O: Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue. Int Urol Nephrol 39: 841-850, 2007.
22. Pardali K and Moustakas A: Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62, 2007.
23. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al: Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 5: 25, 2005.
24. Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ and Wolf HK: Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 438: 116-120, 2001.
25. Li Y, Wen X, Spataro BC, Hu K, Dai C and Liu Y: Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 17: 54-65, 2006.
26. Boyer JF, Balard P, Authier H, et al: Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Res Ther 9: R22, 2007.